부림약품

비상장계속사업자

Bulim.co.kr

이상만

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

부림약품

Business Reg. No. 5028113179 · CEO 이상만

I.Investment Overview

Target부림약품 (5028113179)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명부림약품
영문명Bulim.co.kr
대표자이상만
사업자등록번호5028113179
법인등록번호1701110041997
설립일1993.03.27
종업원수61명

V.Workforce

61

Current headcount · 2026.06 as of

VI.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW5,318.620216,256.120227,256.220238,930.820249,643.52025
영업이익100M KRW15.8202155.6202253.7202388.520241052025
순이익100M KRW18202131202241.6202348.6202449.22025
Item20252024202320222021
자산총계3,317.2억원2,927.1억원2,583.8억원2,201.9억원1,823.7억원
부채총계2,942.6억원2,601.7억원2,307억원1,966.6억원1,619.4억원
자본총계374.6억원325.4억원276.8억원235.2억원204.3억원
매출액9,643.5억원8,930.8억원7,256.2억원6,256.1억원5,318.6억원
영업이익105억원88.5억원53.7억원55.6억원15.8억원
순이익49.2억원48.6억원41.6억원31억원18억원

VII.Financial Ratios

FY2025 basis

1.09%

영업이익률

0.51%

순이익률

1.48%

ROA

13.14%

ROE

785.56%

부채비율

11.29%

자기자본비율

VIII.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

부림약품 투심보고서 | Alpha Lenz